GLPwatch

Effects of GLP-1 receptor agonist on changes in the gut bacterium and the underlying mechanisms.

Sci Rep · 2021

Last updated 2026-05-28

In a mouse study, a single dose of the GLP-1 drug liraglutide increased levels of a gut bacteria component (E. coli) and a stress-related chemical (norepinephrine) in the gut. These changes were blocked when the mice’s nervous system signals to the gut were removed, and the drug’s effects on the gut were linked to activation of the nervous system.

AI summary of the abstract below.

JournalSci Rep, 2021
Citations47
Relative citation ratio3.11
NIH percentile85
Molecules

Abstract

There is a close relationship between the gut microbiota and metabolic disorders. In this study, acute administration of the glucagon-like peptide-1 receptor agonist (GLP-1RA) liraglutide to mice increased the cecal levels of caseinolytic protease B, a component of Escherichia coli, and of norepinephrine. Chemical sympathectomy blocked these events. Norepinephrine was found to pass into the intestinal lumen in vitro. c-Fos staining of the intermediolateral nucleus was identified as indirect evidence of sympathetic nervous system activation of the intestinal tract by GLP-1RA. Under normal conditions, the increase in E. coli did not affect the host. However, in mice with colitis, bacterial translocation was observed with attenuation of tight junction gene expression. This is the first study to investigate the unique underlying mechanisms related the effects of GLP-1RA on changes in the gut bacterium.

Verbatim abstract via PubMed 33911125 ↗